Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: Comparison between European population-based data (EUROCARE-5)

The Lancet Haematology

Volumn 2, Issue 11, 2015, Pages e481-e491

  Mounier, Morgane ^a,b,c,d,e,f   Bossard, Nadine ^b,c,d,g   Remontet, Laurent ^b,c,d,g   Belot, Aurélien ^h   Minicozzi, Pamela ⁱ   De Angelis, Roberta ^j   Capocaccia, Riccardo ^j   Iwaz, Jean ^b,c,d,g   Monnereau, Alain ^a,e   Troussard, Xavier ^k   Sant, Milena ⁱ   Maynadié, Marc ^a,l   Giorgi, Roch ^e,f  

^a UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CNRS   (France)

^e INSERM   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^k CAEN UNIVERSITY HOSPITAL   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; EUROPE; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; COMPARATIVE STUDY; DIFFUSE LARGE B CELL LYMPHOMA; EPIDEMIOLOGY; FEMALE; MALE; MORTALITY; SCOTLAND; WALES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; EUROPE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SCOTLAND; WALES; YOUNG ADULT;

EID: 84955168993     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00155-6     Document Type: Article

References (29)

1. Sant M, Allemani C, De Angelis R, et al, for the EUROCARE-3 Working Group. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008; 44: 579-87.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer Press, 2001.
3. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organization, 2000.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
5. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-31.
6. De Angelis R, Sant M, Coleman MP, et al, for the EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23-34.
7. Marcos-Gragera R, Allemani C, Tereanu C, et al, for the HAEMACARE Working Group. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica 2011; 96: 720-28.
8. Sant M, Minicozzi P, Mounier M, et al, for the EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014; 15: 931-42.
9. Estève J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med 1990; 9: 529-38.
10. Danieli C, Remontet L, Bossard N, Roche L, Belot A. Estimating net survival: the importance of allowing for informative censoring. Stat Med 2012; 31: 775-86.
11. Roche L, Danieli C, Belot A, et al. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 2013; 132: 2359-69.
12. Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics 2012; 68: 113-20.
13. Giorgi R, Abrahamowicz M, Quantin C, et al. A relative survival regression model using B-spline functions to model non-proportional hazards. Stat Med 2003; 22: 2767-84.
14. Remontet L, Bossard N, Belot A, Estève J, for the French network of cancer registries FRANCIM. An overall strategy based on regression models to estimate relative survival and model the effects of prognostic factors in cancer survival studies. Stat Med 2007; 26: 2214-28.
15. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-16.
16. Bossard N, Velten M, Remontet L, et al. Survival of cancer patients in France: a population-based study from the Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007; 43: 149-60.
17. Wynant W, Abrahamowicz M. Impact of the model-building strategy on inference about nonlinear and time-dependent covariate effects in survival analysis. Stat Med 2014; 33: 3318-37.
18. Bosetti C, Bertuccio P, Malvezzi M, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol 2013; 24: 2657-71.
19. Monnereau A, Troussard X, Belot A, et al, for the French Network of Cancer Registries (FRANCIM). Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013; 132: 2378-87.
20. Storm HH, Klint Å, Tryggvadóttir L, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 694-712.
21. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 2015; 385: 1206-18.
22. Al-Hamadani M, Go RS. Stage redistribution and survival among Medicare beneficiaries before and after the approval of positron emission tomography scan for non-Hodgkin lymphoma. Leuk Lymphoma 2015; 56: 1544-46.
23. Le Gouill S, De Guibert S, Planche L, et al, for GELA and GOELAMS. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 2011; 96: 1128-35.
24. Hiddemann W, for the European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 2003; 14: 1163-64.
25. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. Ann Oncol 2001; 12: 1209-10.
26. Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 2012; 157: 159-70.
27. Munro AJ. Leukaemia and lymphoma: why has survival improved? Lancet Oncol 2014; 15: 906-07.
28. Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 2014; 123: 3553-62.
29. Seppä K, Hakulinen T, Pokhrel A. Choosing the net survival method for cancer survival estimation. Eur J Cancer 2015; 51: 1123-29.